Scientists from Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences in Canada studied more than 12,000 patients from 21 countries to evaluate drugs that can prevent cardiovascular diseases (CVD).
These diseases lead to 18 million deaths and about 50 million heart attacks and strokes globally every year, researchers said.
"These are incredibly important findings with potential for significant global impact. If just 10 per cent of the world's population at intermediate risk of CVD is impacted, we are talking about 20 to 30 million people who could be helped by these drugs," said Salim Yusuf from PHRI.
The study involved 228 centres looking at the effects of the three treatments in people at intermediate risk of, but without, clinical heart disease.
Statins proved to significantly and safely reduce CVD events by 25 per cent in patients at intermediate risk without CVD, researchers said.
Antihypertensives did not reduce major CVD events overall in the population studied, but did reduce such events in the group of people with hypertension, but not in those without hypertension, they said.
"Treatment with a statin was remarkably safe and beneficial in our study, regardless of cholesterol or blood pressure levels, age, gender or ethnicity. We are incredibly encouraged by the study's results," said Jackie Bosch from McMaster University.
"These simple methods can be used practically everywhere in the world, and the drugs will become even cheaper as more and more systems and people adopt these therapies," said Yusuf.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
